

Brian O Mahony

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2289333/publications.pdf>

Version: 2024-02-01

41
papers

854
citations

430754

18
h-index

526166

27
g-index

43
all docs

43
docs citations

43
times ranked

685
citing authors

#	ARTICLE	IF	CITATIONS
1	Haemophilia care in Europe - a survey of 35 countries. Haemophilia, 2013, 19, e239-e247.	1.0	67
2	How to discuss gene therapy for haemophilia? A patient and physician perspective. Haemophilia, 2019, 25, 545-557.	1.0	54
3	Achieving the unimaginable: Health equity in haemophilia. Haemophilia, 2020, 26, 17-24.	1.0	54
4	The World Federation of Hemophilia Annual Global Survey 1999â€”2018. Haemophilia, 2020, 26, 591-600.	1.0	50
5	A survey of the outcome of prophylaxis, onâ€”demand treatment or combined treatment in 18â€”35â€”year old men with severe haemophilia in six countries. Haemophilia, 2013, 19, 44-50.	1.0	45
6	The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia. Pilot and Feasibility Studies, 2018, 4, 58.	0.5	34
7	Telehealth for delivery of haemophilia comprehensive care during the COVIDâ€”19 pandemic. Haemophilia, 2020, 26, 984-990.	1.0	31
8	World Federation of Hemophilia Gene Therapy Registry. Haemophilia, 2020, 26, 563-564.	1.0	28
9	Haemophilia care in Europe: a survey of 19 countries. Haemophilia, 2011, 17, 35-40.	1.0	27
10	The Dublin Consensus Statement on vital issues relating to the collection of blood and plasma and the manufacture of plasma products. Vox Sanguinis, 2010, 98, 447-450.	0.7	25
11	Evidence of a disability paradox in patientâ€”reported outcomes in haemophilia. Haemophilia, 2021, 27, 245-252.	1.0	25
12	Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 3074-3077.	1.9	24
13	Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor?. Haemophilia, 2020, 26, 931-933.	1.0	24
14	Haemophilia care in Europe - A survey of 37 countries. Haemophilia, 2017, 23, e259-e266.	1.0	22
15	Survey of coagulation factor concentrates tender and procurement procedures in 38 European Countries. Haemophilia, 2015, 21, 436-443.	1.0	21
16	Creuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies. Haematologica, 2020, 105, 2038-2043.	1.7	21
17	The Dublin Consensus Statement 2011 on vital issues relating to the collection and provision of blood components and plasmaâ€”derived medicinal products. Vox Sanguinis, 2012, 102, 140-143.	0.7	20
18	Value of prophylaxis vs onâ€”demand treatment: Application of a value framework in hemophilia. Haemophilia, 2018, 24, 755-765.	1.0	20

#	ARTICLE	IF	CITATIONS
19	Patientâ€relevant health outcomes for hemophilia care: Development of an international standard outcomes set. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12488.	1.0	20
20	Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies. <i>Haemophilia</i> , 2017, 23, 643-644.	1.0	18
21	Patientâ€centred value framework for haemophilia. <i>Haemophilia</i> , 2018, 24, 873-879.	1.0	17
22	Nonâ€severe haemophilia: Is it benign? â€“ Insights from the PROBE study. <i>Haemophilia</i> , 2021, 27, 17-24.	1.0	16
23	Kreuth <sc>IV</sc>: European consensus proposals for treatment of haemophilia with coagulation factor concentrates. <i>Haemophilia</i> , 2017, 23, 370-375.	1.0	15
24	Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire. <i>BMJ Open</i> , 2018, 8, e021900.	0.8	15
25	Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment. <i>Haemophilia</i> , 2021, 27, 769-782.	1.0	15
26	Testâ€retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains. <i>Haemophilia</i> , 2019, 25, 75-83.	1.0	14
27	Evolution of haemophilia integrated care in the era of gene therapy: Treatment centreâ€™s readiness in United States and EU. <i>Haemophilia</i> , 2021, 27, 511-514.	1.0	13
28	WFH: back to the future. <i>Haemophilia</i> , 2004, 10, 1-8.	1.0	12
29	A systematic review of physical activity in people with haemophilia and its relationship with bleeding phenotype and treatment regimen. <i>Haemophilia</i> , 2021, 27, 544-562.	1.0	12
30	Eliminating Panglossian thinking in development of AAV therapeutics. <i>Molecular Therapy</i> , 2021, 29, 3325-3327.	3.7	12
31	Exploring regional variations in the crossâ€cultural, international implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) study. <i>Haemophilia</i> , 2019, 25, 365-372.	1.0	11
32	Evolution of Haemophilia Care in Europe: 10 years of the principles of care. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 184.	1.2	10
33	Assessments of outcome in haemophilia â€“ a patient perspective. <i>Haemophilia</i> , 2016, 22, e208-9.	1.0	8
34	Realâ€world comparative analysis of bleeding complications and healthâ€related quality of life in patients with haemophilia A and haemophilia B. <i>Haemophilia</i> , 2018, 24, e322-e327.	1.0	8
35	A preliminary application of a haemophilia value framework to emerging therapies in haemophilia. <i>Haemophilia</i> , 2022, 28, 9-18.	1.0	8
36	Progression of hepatitis C in the haemophiliac population in Ireland, after 30 years of infection in the preâ€<sc>DAA</sc> treatment era. <i>Haemophilia</i> , 2017, 23, 712-720.	1.0	7

#	ARTICLE	IF	CITATIONS
37	Comprehensive care on paper only? The challenge for physiotherapy provision in day to day haemophilia practice. <i>Haemophilia</i> , 2021, 27, e284-e286.	1.0	4
38	Recombinant factor IXâ€ƒFc fusion protein in severe hemophilia B: Patientâ€ƒreported outcomes and healthâ€ƒrelated quality of life. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12602.	1.0	4
39	Preparing for tomorrow: Defining a future agenda. <i>Haemophilia</i> , 2022, 28, 35-41.	1.0	4
40	Haemophilia care in Europe: Past progress and future promise. <i>Haemophilia</i> , 2020, 26, 752-758.	1.0	3
41	Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time. <i>Haemophilia</i> , 2021, 27, e596-e608.	1.0	3